FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2964343732> ?p ?o ?g. }

• W2964343732 abstract "This review considered the role of the anal Pap test as a screening test for anal dysplasia in patients at high risk of anal SCC. The screening process is now thought to be improved with the addition of testing for the human papillomavirus (HPV) in high-risk populations. High-resolution anoscopy (a method to view the rectal area, using an anoscope, a lighted instrument inserted into the rectum) rather than routine anoscopy-guided biopsy, is also now considered to be the diagnostic standard.TARGET POPULATION AND CONDITION Anal cancer, like cervical cancer, is a member of a broader group of anogenital cancers known to be associated with sexually transmitted viral HPV infection. Human papillomavirus is extremely prevalent, particularly in young, sexually active populations. Sexual practices involving receptive anal intercourse lead to significantly elevated risk for anal dysplasia and cancer, particularly in those with immune dysfunctions. Anal cancer is rare. It occurs at a rate of about 1 to 2 per 100,000 in the general population. It is the least common of the lower gastrointestinal cancers, representing about 4% of them, in contrast to colorectal cancers, which remain the third most commonly diagnosed malignancy. Certain segments of the population, however, such as HIV-positive men and women, other chronic immune-suppressed patients (e.g., after a transplant), injection drug users, and women with genital dysplasia /cancer, have a high susceptibility to anal cancer. Those with the highest identified risk for anal cancer are HIV-positive homosexual and bisexual men, at a rate of 70 per 100,000 men. The risk for anal cancer is reported to be increasing dramatically in HIV-positive males and females, particularly since the introduction of highly active antiretroviral therapy in the mid-1990s. The introduction of effective viral therapy has been said to have transformed the AIDS epidemic in developed countries into a chronic disease state of long-term immunosuppression. In Ontario, there are about 25,000 people living with HIV infection; more than 6,000 of these are women. About 28% of the newly diagnosed HIV infections are in women, a doubling since 1999. It has also been estimated that 1 of 3 people living with HIV do no know it. HEALTH TECHNOLOGY DESCRIPTION: Anal Pap test screening involves the blind insertion of a swab into the anal canal and fixing cells either on a slide or in fluid for cytological examination. Anal cytology classified by the standardized Bethesda System is the same classification used for cervical cytology. It has 4 categories: normal, atypical squamous cells of uncertain significance, or squamous intraepithelial lesions which are further classified into low- or high-grade lesions. Abnormal cytological findings are subjected to further evaluations by high-resolution anoscopy, a technique similar to cervical colposcopy, and biopsy. Several HPV deoxyribonucleic acid detection technologies such as the Hybrid 11 Capture and the polymerase chain reaction are available to detect and differentiate HPV viral strains. Unlike cervical cancer, there are no universally accepted guidelines or standards of care for anal dysplasia. Moreover, there are no formal screening programs provincially, nationally, or internationally. The New York State Department of Health AIDS Institute has recently recommended (March 2007) annual anal pap testing in high-risk groups. In Ontario, reimbursement exists only for Pap tests for cervical cancer screening. That is, there is no reimbursement for anal Pap testing in men or women, and HPV screening tests for cervical or anal cancer are also not reimbursed.The scientific evidence base was evaluated through a systematic literature review. Assessments of current practices were obtained through consultations with various agencies and individuals including the Ministry of Health and Long-Term Care AIDS Bureau; Public Health Infectious Diseases Branch, Ministry of Health and Long-Term Care; Cancer Care Ontario; HIV/AIDS researchers; pathology experts; and HIV/AIDS clinical program directors. An Ontario-based budget impact was also done.No direct evidence was found for the existence of controlled studies evaluating the effectiveness of anal Pap test screening programs for impact on anal cancer morbidity or mortality. In addition, no studies were found on the use of HPV DNA testing in the screening or diagnostic setting for anal dysplasia. The reported prevalence of HPV infection in high-risk groups, particularly HIV-positive males, however, was sufficiently high to preclude any utility of HPV testing as an adjunct to anal Pap testing. Nine reports involving studies in the United States, United Kingdom, and Canada were identified that evaluated the performance characteristics of anal Pap test screening for anal dysplasia. All involved hospital-based specialty HIV/AIDS care clinics with mainly HIV-positive males. All studies involved experienced pathologists, so the results generally represent best-case scenarios. Estimates of anal Pap test sensitivity and specificity were highly variable, and depended on the varying prevalence of cytology abnormality and differential thresholds for abnormality for both cytology and histopathology. In the largest study of HIV-positive males, sensitivity varied from 46% (95% confidence interval [CI], 36%-56%) to 69% (95% CI, 60%-78%). Specificity ranged from 59% (95% CI, 53%-65%) to 81% (95% CI, 76%-85%). In the only study of HIV-negative males, sensitivity ranged from 26% (95% CI, 5%-47%) to 47% (95% CI, 26%-68%). Specificity ranged from 81% (95% CI, 76%-85%) to 92% (95% CI, 89%-95%). In comparison, cervical Pap testing has also been evaluated mainly in settings where there is a high prevalence of the disease, and estimates of sensitivitykij and specificity were also low and highly variable. In a systematic review involving cervical Pap testing, sensitivity ranged from 30% to 87% (mean, 47%) and specificity from 86% to 100% (mean, 95%).No direct evidence exists to support the effectiveness of an anal Pap test screening program to reduce anal cancer mortality or morbidity. There are, however, strong parallels with cervical pap testing for cervical cancer. Sexually transmitted HPV viral infection is currently the acknowledged common causative agent for both anal and cervical cancer. Anal cancer rates in high-risk populations are approaching those of cervical cancer before the implementation of Pap testing. The anal Pap test, although it has been mainly evaluated only in HIV-positive males, has similar operating characteristics of sensitivity and specificity as the cervical Pap test. In general, the treatment options for precancer dysplasia in the cervix and the anus are similar, but treatment involving a definitive surgical resection in the anus is more limited because of the higher risk of complications. A range of ablative therapies has been applied for anal dysplasia, but evidence on treatment effectiveness, tolerability and durability, particularly in the HIV-positive patient, is limited." @default.
• W2964343732 created "2019-07-30" @default.
• W2964343732 creator A5084751005 @default.
• W2964343732 date "2007-01-01" @default.
• W2964343732 modified "2023-10-03" @default.
• W2964343732 title "Anal dysplasia screening: an evidence-based analysis." @default.
• W2964343732 cites W1247968195 @default.
• W2964343732 cites W1493338266 @default.
• W2964343732 cites W1534815923 @default.
• W2964343732 cites W1873624523 @default.
• W2964343732 cites W1906037527 @default.
• W2964343732 cites W1924942505 @default.
• W2964343732 cites W1967211225 @default.
• W2964343732 cites W1967976040 @default.
• W2964343732 cites W1968447921 @default.
• W2964343732 cites W1968554847 @default.
• W2964343732 cites W1970598792 @default.
• W2964343732 cites W1972992401 @default.
• W2964343732 cites W1975388998 @default.
• W2964343732 cites W1976245963 @default.
• W2964343732 cites W1977957554 @default.
• W2964343732 cites W1979947230 @default.
• W2964343732 cites W1981052279 @default.
• W2964343732 cites W1982103755 @default.
• W2964343732 cites W1986312175 @default.
• W2964343732 cites W1987350137 @default.
• W2964343732 cites W1987879409 @default.
• W2964343732 cites W1988558796 @default.
• W2964343732 cites W1990534466 @default.
• W2964343732 cites W1991949008 @default.
• W2964343732 cites W1992403141 @default.
• W2964343732 cites W2000476016 @default.
• W2964343732 cites W2000836190 @default.
• W2964343732 cites W2001272282 @default.
• W2964343732 cites W2001359840 @default.
• W2964343732 cites W2004405589 @default.
• W2964343732 cites W2004674700 @default.
• W2964343732 cites W2007910211 @default.
• W2964343732 cites W2008750108 @default.
• W2964343732 cites W2011898088 @default.
• W2964343732 cites W2012508042 @default.
• W2964343732 cites W2018087970 @default.
• W2964343732 cites W2027261752 @default.
• W2964343732 cites W2032277129 @default.
• W2964343732 cites W2032418001 @default.
• W2964343732 cites W2036289356 @default.
• W2964343732 cites W2037886393 @default.
• W2964343732 cites W2037977447 @default.
• W2964343732 cites W2042147683 @default.
• W2964343732 cites W2043746949 @default.
• W2964343732 cites W2054530512 @default.
• W2964343732 cites W2062272945 @default.
• W2964343732 cites W2064562683 @default.
• W2964343732 cites W2068260090 @default.
• W2964343732 cites W2078150697 @default.
• W2964343732 cites W2082112921 @default.
• W2964343732 cites W2082618248 @default.
• W2964343732 cites W2089150671 @default.
• W2964343732 cites W2089629585 @default.
• W2964343732 cites W2093150743 @default.
• W2964343732 cites W2094581205 @default.
• W2964343732 cites W2094862472 @default.
• W2964343732 cites W2095965063 @default.
• W2964343732 cites W2096478290 @default.
• W2964343732 cites W2103571623 @default.
• W2964343732 cites W2106993950 @default.
• W2964343732 cites W2114813165 @default.
• W2964343732 cites W2118122224 @default.
• W2964343732 cites W2121189112 @default.
• W2964343732 cites W2125265709 @default.
• W2964343732 cites W2126861692 @default.
• W2964343732 cites W2128247901 @default.
• W2964343732 cites W2129745672 @default.
• W2964343732 cites W2130223156 @default.
• W2964343732 cites W2133765716 @default.
• W2964343732 cites W2134829083 @default.
• W2964343732 cites W2140654077 @default.
• W2964343732 cites W2141005744 @default.
• W2964343732 cites W2147675930 @default.
• W2964343732 cites W2153043270 @default.
• W2964343732 cites W2154865008 @default.
• W2964343732 cites W2157515556 @default.
• W2964343732 cites W2160438825 @default.
• W2964343732 cites W2174935414 @default.
• W2964343732 cites W2324299759 @default.
• W2964343732 cites W2324913702 @default.
• W2964343732 cites W2330975960 @default.
• W2964343732 cites W2337028134 @default.
• W2964343732 cites W2404560508 @default.
• W2964343732 cites W84803140 @default.
• W2964343732 cites W2097378609 @default.
• W2964343732 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3377578" @default.
• W2964343732 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23074504" @default.
• W2964343732 hasPublicationYear "2007" @default.
• W2964343732 type Work @default.
• W2964343732 sameAs 2964343732 @default.
• W2964343732 citedByCount "9" @default.
• W2964343732 countsByYear W29643437322015 @default.
• W2964343732 countsByYear W29643437322016 @default.
• W2964343732 countsByYear W29643437322018 @default.

• next